Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
Brief Summary: This study is a pilot study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer. More specifically, this is a randomized, multi-center, open label, phase II study for Homologous Recombination Deficiency(HRD)+ patients and a biomarker-driven multiple-arm phase II study for Homologous Recombination Deficiency(HRD)- patients.

This study will consist of a number of study modules (substudies), each evaluating the antitumor activity of targeted agents in patients whose tumors express specific phenotype relevant to the molecules under investigation.


Options:
A: Arm Label: Patupilone; Type: EXPERIMENTAL; Interventions: Drug: EPO906 (Patupilone) | Arm Label: doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: doxorubicin | Intervention Type: DRUG; Name: EPO906 (Patupilone); Assigned to Arm(s): Patupilone | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): doxorubicin
B: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly; Assigned to Arm(s): Chemotherapy
C: Arm Label: olaparib + cediranib; Type: EXPERIMENTAL; Interventions: Drug: olaparib+cediranib combination therapy | Arm Label: durvalumab + olaparib; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + olaparib combination therapy | Arm Label: durvalumab + chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + chemotherapy treatment | Arm Label: durvalumab + tremelimumab + chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + tremelimumab + chemotherapy treatment | Arm Label: durvalumab + tremelimumab + paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: durvalumab + tremelimumab + paclitaxel treatment | Arm Label: durvalumab +chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: durvalumab +chemotherapy treatment | Intervention Type: DRUG; Name: olaparib+cediranib combination therapy; Assigned to Arm(s): olaparib + cediranib | Intervention Type: DRUG; Name: durvalumab + olaparib combination therapy; Assigned to Arm(s): durvalumab + olaparib | Intervention Type: DRUG; Name: durvalumab + chemotherapy treatment; Assigned to Arm(s): durvalumab + chemotherapy | Intervention Type: DRUG; Name: durvalumab + tremelimumab + chemotherapy treatment; Assigned to Arm(s): durvalumab + tremelimumab + chemotherapy | Intervention Type: DRUG; Name: durvalumab + tremelimumab + paclitaxel treatment; Assigned to Arm(s): durvalumab + tremelimumab + paclitaxel | Intervention Type: DRUG; Name: durvalumab +chemotherapy treatment; Assigned to Arm(s): durvalumab +chemotherapy
D: Arm Label: PLD 40 mg/m2 plus VTX-2337; Type: EXPERIMENTAL; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Drug: VTX-2337 | Arm Label: PLD 40 mg/m2 plus placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Drug: Placebo | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD 40 mg/m2 plus VTX-2337, PLD 40 mg/m2 plus placebo | Intervention Type: DRUG; Name: VTX-2337; Assigned to Arm(s): PLD 40 mg/m2 plus VTX-2337 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLD 40 mg/m2 plus placebo

Answer: C